Tag: lupus nephritis market growth

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Lupus Nephritis Market Size, Value And Growth Trends Through 2030

The lupus nephritis market experienced robust expansion recently, projecting a rise from $2.08 billion in 2025 to $2.24 billion in 2026, reflecting a compound annual growth rate of 7.7%. This historical growth trajectory was fueled by several key factors, including the escalating incidence of systemic lupus erythematosus, advancements in kidney biopsy and diagnostic methods, the extensive application of corticosteroids for treatment, the expanding availability of hospital-based nephrology services, and heightened public understanding of autoimmune kidney disorders.

The lupus nephritis market is poised for significant expansion, projecting a reach of $2.98 billion by 2030 with a compound annual growth rate (CAGR) of 7.4%. This anticipated growth over the forecast period is fueled by several key factors, including increased funding for biologic drug research, a greater emphasis on early intervention strategies to avert kidney damage, the wider acceptance of combined treatment approaches, the proliferation of specialized kidney care centers, and escalating healthcare expenditures dedicated to managing autoimmune conditions. Key developments shaping this market include a heightened focus on prompt diagnosis and continuous patient monitoring, the increasing utilization of immunosuppressive and biologic treatments, a growing inclination towards tailored therapeutic plans, the development of more comprehensive long-term disease management frameworks, and elevated public and professional awareness regarding autoimmune kidney afflictions.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22044&type=smp

Lupus Nephritis Market Growth Drivers: What Factors Are Accelerating Expansion?

An upward trend in the incidence of genetic predisposition is anticipated to fuel the expansion of the lupus nephritis market. This inherent genetic susceptibility means individuals possess inherited characteristics that heighten their risk for specific ailments. The rise in such predispositions stems from a combination of inherited factors, external environmental impacts, and alterations

Lupus Nephritis Market Categorization By Product Type And Application

The lupus nephritis market covered in this report is segmented –

1) By Stage: Class 1, Class 2, Class 3, Other Stages

2) By Drug Class: Immunosuppressive Drugs, Corticosteroids, Biological Agents, Antimalarial Drugs

3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

5) By End-User: Hospitals, Specialty Clinics, Other End-Users

Subsegments:

1) By Class 1: Asymptomatic Cases, Mild Proteinuria, Incidental Diagnosis

2) By Class 2: Mild Hematuria, Low-Grade Proteinuria, Minimal Immune Complex Deposition

3) By Class 3: Active Lesions, Chronic Sclerotic Lesions, Crescent Formation

4) By Other Stages: Class 4 (Diffuse Lupus Nephritis), Class 5 (Membranous Lupus Nephritis), Class 6 (Advanced Sclerotic Lupus Nephritis)

Lupus Nephritis Market Trends: What Is Shaping Future Industry Growth?

Key players within the lupus nephritis sector are prioritizing the innovation of sophisticated second-generation calcineurin inhibitors aimed at boosting therapeutic effectiveness and fostering better long-term kidney health for individuals afflicted with the condition. These advanced calcineurin inhibitors serve to mitigate inflammation and avert renal deterioration in lupus nephritis by regulating the body’s immune responses. A notable development occurred in September of 2024 when Aurinia Pharmaceuticals Inc., a biopharmaceutical firm headquartered in Canada that is currently in its commercial stage, revealed that LUPKYNIS, also known as voclosporin, received endorsement from the Japanese Ministry of Health, Labour, and Welfare for the management of lupus nephritis. This regulatory clearance permits the utilization of voclosporin alongside mycophenolate mofetil (MMF), a recommendation stemming from the findings of the AURORA Clinical Program, which substantiated its safety profile and beneficial effects, thereby representing a pivotal advancement in broadening the therapeutic choices available to lupus nephritis sufferers in Japan and consequently enhancing both disease control and patient prognoses.

Lupus Nephritis Market Company Landscape And Strategic Competition

Major companies operating in the lupus nephritis market are F Hoffmann La Roche Ltd, Bristol Myers Squibb, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, AstraZeneca PLC, Pfizer Inc, Johnson and Johnson, Merck and Co Inc, Sanofi, AbbVie Inc, Bayer AG, Amgen Inc, UCB SA, Otsuka Pharmaceutical Co Ltd, Aurinia Pharmaceuticals Inc, RemeGen Co Ltd, Kezar Life Sciences, Equillium Inc, Kyverna Therapeutics Inc, Biogen Inc

Access The Complete Lupus Nephritis Market Report:

https://www.thebusinessresearchcompany.com/report/lupus-nephritis-global-market-report

Lupus Nephritis Market Geographic Distribution And Regional Opportunities

Asia-Pacificwas the largest region in the lupus nephritis market in 2025. The regions covered in the lupus nephritis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Lupus Nephritis Market Size, Value And Growth Trends Through 2030

The lupus nephritis market experienced robust expansion recently, projecting a rise from $2.08 billion in 2025 to $2.24 billion in 2026, reflecting a compound annual growth rate of 7.7%. This historical growth trajectory was fueled by several key factors, including the escalating incidence of systemic lupus erythematosus, advancements in kidney biopsy and diagnostic methods, the extensive application of corticosteroids for treatment, the expanding availability of hospital-based nephrology services, and heightened public understanding of autoimmune kidney disorders.

The lupus nephritis market is poised for significant expansion, projecting a reach of $2.98 billion by 2030 with a compound annual growth rate (CAGR) of 7.4%. This anticipated growth over the forecast period is fueled by several key factors, including increased funding for biologic drug research, a greater emphasis on early intervention strategies to avert kidney damage, the wider acceptance of combined treatment approaches, the proliferation of specialized kidney care centers, and escalating healthcare expenditures dedicated to managing autoimmune conditions. Key developments shaping this market include a heightened focus on prompt diagnosis and continuous patient monitoring, the increasing utilization of immunosuppressive and biologic treatments, a growing inclination towards tailored therapeutic plans, the development of more comprehensive long-term disease management frameworks, and elevated public and professional awareness regarding autoimmune kidney afflictions.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22044&type=smp

Lupus Nephritis Market Growth Drivers: What Factors Are Accelerating Expansion?

An upward trend in the incidence of genetic predisposition is anticipated to fuel the expansion of the lupus nephritis market. This inherent genetic susceptibility means individuals possess inherited characteristics that heighten their risk for specific ailments. The rise in such predispositions stems from a combination of inherited factors, external environmental impacts, and alterations

Lupus Nephritis Market Categorization By Product Type And Application

The lupus nephritis market covered in this report is segmented –

1) By Stage: Class 1, Class 2, Class 3, Other Stages

2) By Drug Class: Immunosuppressive Drugs, Corticosteroids, Biological Agents, Antimalarial Drugs

3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

5) By End-User: Hospitals, Specialty Clinics, Other End-Users

Subsegments:

1) By Class 1: Asymptomatic Cases, Mild Proteinuria, Incidental Diagnosis

2) By Class 2: Mild Hematuria, Low-Grade Proteinuria, Minimal Immune Complex Deposition

3) By Class 3: Active Lesions, Chronic Sclerotic Lesions, Crescent Formation

4) By Other Stages: Class 4 (Diffuse Lupus Nephritis), Class 5 (Membranous Lupus Nephritis), Class 6 (Advanced Sclerotic Lupus Nephritis)

Lupus Nephritis Market Trends: What Is Shaping Future Industry Growth?

Key players within the lupus nephritis sector are prioritizing the innovation of sophisticated second-generation calcineurin inhibitors aimed at boosting therapeutic effectiveness and fostering better long-term kidney health for individuals afflicted with the condition. These advanced calcineurin inhibitors serve to mitigate inflammation and avert renal deterioration in lupus nephritis by regulating the body’s immune responses. A notable development occurred in September of 2024 when Aurinia Pharmaceuticals Inc., a biopharmaceutical firm headquartered in Canada that is currently in its commercial stage, revealed that LUPKYNIS, also known as voclosporin, received endorsement from the Japanese Ministry of Health, Labour, and Welfare for the management of lupus nephritis. This regulatory clearance permits the utilization of voclosporin alongside mycophenolate mofetil (MMF), a recommendation stemming from the findings of the AURORA Clinical Program, which substantiated its safety profile and beneficial effects, thereby representing a pivotal advancement in broadening the therapeutic choices available to lupus nephritis sufferers in Japan and consequently enhancing both disease control and patient prognoses.

Lupus Nephritis Market Company Landscape And Strategic Competition

Major companies operating in the lupus nephritis market are F Hoffmann La Roche Ltd, Bristol Myers Squibb, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, AstraZeneca PLC, Pfizer Inc, Johnson and Johnson, Merck and Co Inc, Sanofi, AbbVie Inc, Bayer AG, Amgen Inc, UCB SA, Otsuka Pharmaceutical Co Ltd, Aurinia Pharmaceuticals Inc, RemeGen Co Ltd, Kezar Life Sciences, Equillium Inc, Kyverna Therapeutics Inc, Biogen Inc

Access The Complete Lupus Nephritis Market Report:

https://www.thebusinessresearchcompany.com/report/lupus-nephritis-global-market-report

Lupus Nephritis Market Geographic Distribution And Regional Opportunities

Asia-Pacificwas the largest region in the lupus nephritis market in 2025. The regions covered in the lupus nephritis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Lupus Nephritis Market Size, Value And Growth Trends Through 2030

The lupus nephritis market experienced robust expansion recently, projecting a rise from $2.08 billion in 2025 to $2.24 billion in 2026, reflecting a compound annual growth rate of 7.7%. This historical growth trajectory was fueled by several key factors, including the escalating incidence of systemic lupus erythematosus, advancements in kidney biopsy and diagnostic methods, the extensive application of corticosteroids for treatment, the expanding availability of hospital-based nephrology services, and heightened public understanding of autoimmune kidney disorders.

The lupus nephritis market is poised for significant expansion, projecting a reach of $2.98 billion by 2030 with a compound annual growth rate (CAGR) of 7.4%. This anticipated growth over the forecast period is fueled by several key factors, including increased funding for biologic drug research, a greater emphasis on early intervention strategies to avert kidney damage, the wider acceptance of combined treatment approaches, the proliferation of specialized kidney care centers, and escalating healthcare expenditures dedicated to managing autoimmune conditions. Key developments shaping this market include a heightened focus on prompt diagnosis and continuous patient monitoring, the increasing utilization of immunosuppressive and biologic treatments, a growing inclination towards tailored therapeutic plans, the development of more comprehensive long-term disease management frameworks, and elevated public and professional awareness regarding autoimmune kidney afflictions.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22044&type=smp

Lupus Nephritis Market Growth Drivers: What Factors Are Accelerating Expansion?

An upward trend in the incidence of genetic predisposition is anticipated to fuel the expansion of the lupus nephritis market. This inherent genetic susceptibility means individuals possess inherited characteristics that heighten their risk for specific ailments. The rise in such predispositions stems from a combination of inherited factors, external environmental impacts, and alterations

Lupus Nephritis Market Categorization By Product Type And Application

The lupus nephritis market covered in this report is segmented –

1) By Stage: Class 1, Class 2, Class 3, Other Stages

2) By Drug Class: Immunosuppressive Drugs, Corticosteroids, Biological Agents, Antimalarial Drugs

3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

5) By End-User: Hospitals, Specialty Clinics, Other End-Users

Subsegments:

1) By Class 1: Asymptomatic Cases, Mild Proteinuria, Incidental Diagnosis

2) By Class 2: Mild Hematuria, Low-Grade Proteinuria, Minimal Immune Complex Deposition

3) By Class 3: Active Lesions, Chronic Sclerotic Lesions, Crescent Formation

4) By Other Stages: Class 4 (Diffuse Lupus Nephritis), Class 5 (Membranous Lupus Nephritis), Class 6 (Advanced Sclerotic Lupus Nephritis)

Lupus Nephritis Market Trends: What Is Shaping Future Industry Growth?

Key players within the lupus nephritis sector are prioritizing the innovation of sophisticated second-generation calcineurin inhibitors aimed at boosting therapeutic effectiveness and fostering better long-term kidney health for individuals afflicted with the condition. These advanced calcineurin inhibitors serve to mitigate inflammation and avert renal deterioration in lupus nephritis by regulating the body’s immune responses. A notable development occurred in September of 2024 when Aurinia Pharmaceuticals Inc., a biopharmaceutical firm headquartered in Canada that is currently in its commercial stage, revealed that LUPKYNIS, also known as voclosporin, received endorsement from the Japanese Ministry of Health, Labour, and Welfare for the management of lupus nephritis. This regulatory clearance permits the utilization of voclosporin alongside mycophenolate mofetil (MMF), a recommendation stemming from the findings of the AURORA Clinical Program, which substantiated its safety profile and beneficial effects, thereby representing a pivotal advancement in broadening the therapeutic choices available to lupus nephritis sufferers in Japan and consequently enhancing both disease control and patient prognoses.

Lupus Nephritis Market Company Landscape And Strategic Competition

Major companies operating in the lupus nephritis market are F Hoffmann La Roche Ltd, Bristol Myers Squibb, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, AstraZeneca PLC, Pfizer Inc, Johnson and Johnson, Merck and Co Inc, Sanofi, AbbVie Inc, Bayer AG, Amgen Inc, UCB SA, Otsuka Pharmaceutical Co Ltd, Aurinia Pharmaceuticals Inc, RemeGen Co Ltd, Kezar Life Sciences, Equillium Inc, Kyverna Therapeutics Inc, Biogen Inc

Access The Complete Lupus Nephritis Market Report:

https://www.thebusinessresearchcompany.com/report/lupus-nephritis-global-market-report

Lupus Nephritis Market Geographic Distribution And Regional Opportunities

Asia-Pacificwas the largest region in the lupus nephritis market in 2025. The regions covered in the lupus nephritis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Market Size Is Forecasted For The Lupus Nephritis Market By 2030 Based On Its 2026 Value?

The lupus nephritis market size has shown significant expansion in recent years. It is anticipated to increase from $2.08 billion in 2025 to $2.24 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 7.7%. This growth in the historic period is attributable to the increasing prevalence of systemic lupus erythematosus, advancements in kidney biopsy and diagnostic practices, the widespread use of corticosteroids in treatment, the expansion of hospital-based nephrology care, and heightened awareness of autoimmune kidney diseases.

The lupus nephritis market size is poised for significant expansion in the coming years. It is projected to reach $2.98 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.4%. This growth over the forecast period is propelled by factors such as increasing investment in biologic drug development, a greater emphasis on early intervention to prevent kidney failure, the rising adoption of combination therapy regimens, the expansion of specialty nephrology clinics, and increased healthcare spending dedicated to managing autoimmune diseases. Prominent trends anticipated during this period include a heightened focus on early diagnosis and disease monitoring, the growing uptake of immunosuppressive and biologic therapies, an increasing push towards personalized treatment approaches, the broadening of long-term disease management strategies, and rising awareness regarding autoimmune kidney complications.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22044&type=smp

Which Core Factors Are Supporting The Expansion Of The Lupus Nephritis Market?

The lupus nephritis market is anticipated to expand, driven by the rising occurrence of genetic predisposition. Genetic predisposition describes inherited genetic characteristics that elevate an individual’s susceptibility to specific diseases or conditions. This increase in genetic predisposition stems from elements like inheritance patterns, environmental factors, and genetic mutations. Its growing prevalence significantly contributes to the onset of lupus nephritis, highlighting how inherited genetic elements influence autoimmune conditions, especially those impacting renal function. For example, in October 2024, the UK-based national charity, the Cystic Fibrosis Trust, reported via its UK CF Registry that registered patients increased from 11,148 in 2022 to 11,318 in 2024, marking a 1.52% rise in individuals with cystic fibrosis (CF). Consequently, the rising incidence of genetic predisposition is fueling the expansion of the lupus nephritis market.

What Are The Core Segment Classifications In The Lupus Nephritis Market?

The lupus nephritis market covered in this report is segmented –

1) By Stage: Class 1, Class 2, Class 3, Other Stages

2) By Drug Class: Immunosuppressive Drugs, Corticosteroids, Biological Agents, Antimalarial Drugs

3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

5) By End-User: Hospitals, Specialty Clinics, Other End-Users

Subsegments:

1) By Class 1: Asymptomatic Cases, Mild Proteinuria, Incidental Diagnosis

2) By Class 2: Mild Hematuria, Low-Grade Proteinuria, Minimal Immune Complex Deposition

3) By Class 3: Active Lesions, Chronic Sclerotic Lesions, Crescent Formation

4) By Other Stages: Class 4 (Diffuse Lupus Nephritis), Class 5 (Membranous Lupus Nephritis), Class 6 (Advanced Sclerotic Lupus Nephritis)

Which Trends Are Guiding The Development Of The Lupus Nephritis Market?

Major companies active in the lupus nephritis market are concentrating on developing sophisticated second-generation calcineurin inhibitors, aiming to elevate treatment efficacy and improve long-term kidney health outcomes for patients. These second-generation calcineurin inhibitors are applied in lupus nephritis to diminish inflammation and avert kidney damage through the modulation of immune responses. For instance, in September 2024, Aurinia Pharmaceuticals Inc., a Canada-based commercial-stage biopharmaceutical company, announced that LUPKYNIS (voclosporin) received approval from the Japanese Ministry of Health, Labour, and Welfare for the management of lupus nephritis. This authorization permits voclosporin to be administered in conjunction with mycophenolate mofetil (MMF), based on data from the AURORA Clinical Program which demonstrated its safety and effectiveness. The approval represents a crucial achievement in expanding therapeutic alternatives for lupus nephritis patients in Japan, leading to improved disease management and patient outcomes.

Who Are The Companies Shaping The Lupus Nephritis Market Landscape?

Major companies operating in the lupus nephritis market are F Hoffmann La Roche Ltd, Bristol Myers Squibb, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, AstraZeneca PLC, Pfizer Inc, Johnson and Johnson, Merck and Co Inc, Sanofi, AbbVie Inc, Bayer AG, Amgen Inc, UCB SA, Otsuka Pharmaceutical Co Ltd, Aurinia Pharmaceuticals Inc, RemeGen Co Ltd, Kezar Life Sciences, Equillium Inc, Kyverna Therapeutics Inc, Biogen Inc

Access The Complete Lupus Nephritis Market Report:

https://www.thebusinessresearchcompany.com/report/lupus-nephritis-global-market-report

Which Regional Market Leads The Lupus Nephritis Market?

Asia-Pacific was the largest region in the lupus nephritis market in 2025. The regions covered in the lupus nephritis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Lupus Nephritis Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=22044&type=smp

Browse Through More Reports Similar to the Global Lupus Nephritis Market 2026, By The Business Research Company

Cutaneous Lupus Erythematosus Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/cutaneous-lupus-erythematosus-global-market-report

Lupus Therapeutics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/lupus-therapeutics-global-market-report

Kidney Disease Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/kidney-disease-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Does The Market Size Of The Lupus Nephritis Market Compare Between 2026 And 2030?

The lupus nephritis market has experienced substantial growth in recent years. It is projected to expand from $2.08 billion in 2025 to $2.24 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.7%. The market’s historical growth was fueled by the increasing prevalence of systemic lupus erythematosus, refined kidney biopsy and diagnostic techniques, the broad application of corticosteroids in treatment, expanding hospital-based nephrology care, and elevated awareness of autoimmune kidney diseases.

The lupus nephritis market size is projected to experience substantial expansion in the coming years, forecast to reach $2.98 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.4%. This anticipated growth during the forecast period is attributed to factors such as rising investment in biologic drug development, an increasing focus on early intervention to prevent kidney failure, the growing adoption of combination therapy regimens, the expansion of specialty nephrology clinics, and increasing healthcare spending on autoimmune disease management. Major trends expected in this period include a heightened focus on early diagnosis and disease monitoring, the growing uptake of immunosuppressive and biologic therapies, an increasing emphasis on personalized treatment approaches, the expansion of long-term disease management strategies, and rising awareness of autoimmune kidney complications.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22044&type=smp

What Significant Factors Are Influencing The Lupus Nephritis Market Expansion?

The expanding presence of genetic susceptibility is anticipated to drive the future expansion of the lupus nephritis market. Genetic predisposition denotes inherited genetic characteristics in an individual that elevate their risk of developing specific illnesses or health conditions. The rising occurrence of genetic predisposition stems from elements like inheritance, environmental factors, and alterations in particular genes. This growing prevalence of genetic predisposition significantly contributes to the onset of lupus nephritis, highlighting the influence of inherited genetic elements in autoimmune conditions, especially those impacting kidney function. As an illustration, the Cystic Fibrosis Trust, a national charity in the UK, reported in October 2024 that the UK CF Registry had 11,148 registered patients in 2022, a figure that climbed to 11,318 by 2024, indicating a 1.52% rise in individuals affected by cystic fibrosis (CF). Consequently, the escalating prevalence of genetic predisposition is fueling the expansion of the lupus nephritis market.

How Is The Lupus Nephritis Market Organized By Segment Classification?

The lupus nephritis market covered in this report is segmented –

1) By Stage: Class 1, Class 2, Class 3, Other Stages

2) By Drug Class: Immunosuppressive Drugs, Corticosteroids, Biological Agents, Antimalarial Drugs

3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

5) By End-User: Hospitals, Specialty Clinics, Other End-Users

Subsegments:

1) By Class 1: Asymptomatic Cases, Mild Proteinuria, Incidental Diagnosis

2) By Class 2: Mild Hematuria, Low-Grade Proteinuria, Minimal Immune Complex Deposition

3) By Class 3: Active Lesions, Chronic Sclerotic Lesions, Crescent Formation

4) By Other Stages: Class 4 (Diffuse Lupus Nephritis), Class 5 (Membranous Lupus Nephritis), Class 6 (Advanced Sclerotic Lupus Nephritis)

What Trends Are Affecting The Direction Of The Lupus Nephritis Market?

Prominent companies within the lupus nephritis market are concentrating on advancing second-generation calcineurin inhibitors, seeking to elevate treatment effectiveness and foster better long-term kidney outcomes for individuals. These second-generation calcineurin inhibitors are utilized in lupus nephritis to mitigate inflammation and avert renal damage by moderating immune responses. For example, in September 2024, Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical firm based in Canada, declared that the Japanese Ministry of Health, Labour, and Welfare had granted approval for LUPKYNIS (voclosporin) in the treatment of lupus nephritis. This authorization permits voclosporin’s application alongside mycophenolate mofetil (MMF), supported by information from the AURORA Clinical Program, which evidenced its safety and efficacy. The approval constitutes a vital landmark in broadening the range of treatment alternatives for lupus nephritis patients in Japan, thereby improving disease oversight and patient results.

Who Are The Industry Participants Involved In The Lupus Nephritis Market?

Major companies operating in the lupus nephritis market are F Hoffmann La Roche Ltd, Bristol Myers Squibb, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, AstraZeneca PLC, Pfizer Inc, Johnson and Johnson, Merck and Co Inc, Sanofi, AbbVie Inc, Bayer AG, Amgen Inc, UCB SA, Otsuka Pharmaceutical Co Ltd, Aurinia Pharmaceuticals Inc, RemeGen Co Ltd, Kezar Life Sciences, Equillium Inc, Kyverna Therapeutics Inc, Biogen Inc

Get The Full Lupus Nephritis Market Report:

https://www.thebusinessresearchcompany.com/report/lupus-nephritis-global-market-report

Which Region Is The Leading Market For The Lupus Nephritis Market?

Asia-Pacific was the largest region in the lupus nephritis market in 2025. The regions covered in the lupus nephritis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Lupus Nephritis Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/lupus-nephritis-global-market-report

Browse Through More Reports Similar to the Global Lupus Nephritis Market 2026, By The Business Research Company

Cutaneous Lupus Erythematosus Market Report 2026

https://www.thebusinessresearchcompany.com/report/cutaneous-lupus-erythematosus-global-market-report

Lupus Therapeutics Market Report

https://www.thebusinessresearchcompany.com/report/lupus-therapeutics-global-market-report

Kidney Disease Market Report

https://www.thebusinessresearchcompany.com/report/kidney-disease-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Expected Market Size Of The Lupus Nephritis Market From 2026 To 2030?

The lupus nephritis market has experienced significant expansion in recent years. It is anticipated to grow from $2.08 billion in 2025 to $2.24 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.7%. This growth observed in the past can be attributed to factors such as the increasing prevalence of systemic lupus erythematosus, improved kidney biopsy and diagnostic practices, the widespread use of corticosteroids in treatment, the expansion of hospital-based nephrology care, and increased awareness of autoimmune kidney diseases.

The market for lupus nephritis is projected to experience substantial expansion in the coming years. By 2030, this market is anticipated to reach a value of $2.98 billion, demonstrating a compound annual growth rate (CAGR) of 7.4%. This projected growth is linked to several factors, including increased investment in the development of biologic drugs, a greater emphasis on early intervention to avert kidney failure, the wider acceptance of combination therapy treatments, the proliferation of specialized nephrology clinics, and increased expenditure on managing autoimmune diseases within healthcare. Key developments expected during this period involve a heightened focus on timely diagnosis and monitoring of the disease, the increasing use of immunosuppressive and biologic therapies, a greater drive towards tailored treatment strategies, the broadening of long-term disease management plans, and an improved understanding of kidney complications arising from autoimmune conditions.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22044&type=smp

What Key Drivers Are Influencing The Growth Of The Lupus Nephritis Market?

The increasing occurrence of genetic predisposition is projected to drive the expansion of the lupus nephritis market in the foreseeable future. Genetic predisposition refers to an individual’s inherited genetic traits that heighten their probability of developing particular diseases or conditions. The rising incidence of genetic predisposition results from factors such as inheritance, environmental influences, and mutations in specific genes. This growing prevalence plays a vital role in the manifestation of lupus nephritis, underscoring the significance of inherited genetic factors in autoimmune diseases, particularly those that affect kidney function. For instance, in October 2024, according to the Cystic Fibrosis Trust, a UK-based national charity, the UK CF Registry recorded 11,148 registered patients in 2022, which increased to 11,318 in 2024, reflecting a 1.52% increase in individuals with cystic fibrosis (CF). Consequently, the increasing prevalence of genetic predisposition is stimulating the growth of the lupus nephritis market.

Which Segments Are Included In The Analysis Of The Lupus Nephritis Market?

The lupus nephritis market covered in this report is segmented –

1) By Stage: Class 1, Class 2, Class 3, Other Stages

2) By Drug Class: Immunosuppressive Drugs, Corticosteroids, Biological Agents, Antimalarial Drugs

3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

5) By End-User: Hospitals, Specialty Clinics, Other End-Users

Subsegments:

1) By Class 1: Asymptomatic Cases, Mild Proteinuria, Incidental Diagnosis

2) By Class 2: Mild Hematuria, Low-Grade Proteinuria, Minimal Immune Complex Deposition

3) By Class 3: Active Lesions, Chronic Sclerotic Lesions, Crescent Formation

4) By Other Stages: Class 4 (Diffuse Lupus Nephritis), Class 5 (Membranous Lupus Nephritis), Class 6 (Advanced Sclerotic Lupus Nephritis)

How Are Trends Transforming The Lupus Nephritis Market Landscape?

Leading companies active in the lupus nephritis market are directing their efforts toward developing sophisticated second-generation calcineurin inhibitors, with the goal of enhancing treatment efficacy and improving long-term kidney outcomes for patients. These second-generation calcineurin inhibitors are utilized in lupus nephritis to alleviate inflammation and prevent kidney damage by moderating immune responses. For instance, in September 2024, Aurinia Pharmaceuticals Inc., a Canada-based commercial-stage biopharmaceutical company, announced that the Japanese Ministry of Health, Labour, and Welfare approved LUPKYNIS (voclosporin) for the treatment of lupus nephritis. This authorization permits voclosporin to be administered in conjunction with mycophenolate mofetil (MMF), based on findings from the AURORA Clinical Program, which confirmed its safety and efficacy. The approval signifies a major step forward in expanding therapeutic alternatives for lupus nephritis patients in Japan, leading to improved disease management and patient results.

Which Key Industry Participants Are Active In The Lupus Nephritis Market?

Major companies operating in the lupus nephritis market are F Hoffmann La Roche Ltd, Bristol Myers Squibb, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, AstraZeneca PLC, Pfizer Inc, Johnson and Johnson, Merck and Co Inc, Sanofi, AbbVie Inc, Bayer AG, Amgen Inc, UCB SA, Otsuka Pharmaceutical Co Ltd, Aurinia Pharmaceuticals Inc, RemeGen Co Ltd, Kezar Life Sciences, Equillium Inc, Kyverna Therapeutics Inc, Biogen Inc

Read the full lupus nephritis market report here:

https://www.thebusinessresearchcompany.com/report/lupus-nephritis-global-market-report

Which Region Is Expected To Register The Fastest Growth In The Lupus Nephritis Market?

Asia-Pacific was the largest region in the lupus nephritis market in 2025. The regions covered in the lupus nephritis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Lupus Nephritis Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=22044&type=smp

Browse Through More Reports Similar to the Global Lupus Nephritis Market 2026, By The Business Research Company

Cutaneous Lupus Erythematosus Global Market Report

https://www.thebusinessresearchcompany.com/report/cutaneous-lupus-erythematosus-global-market-report

Lupus Therapeutics Global Market Report

https://www.thebusinessresearchcompany.com/report/lupus-therapeutics-global-market-report

Kidney Disease Global Market Report

https://www.thebusinessresearchcompany.com/report/kidney-disease-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model